---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-25-000037"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:37:56.648997+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Praxis Essential3 interim analysis recommends futility; studies continue to Q3 2025

## Summary
- IDMC recommended stopping Essential3 Study 1 for futility; Praxis continues both studies to completion.
- Topline results for Essential3 now expected Q3 2025; NDA decision after final data.
- Cash, equivalents and marketable securities of $469.5M as of Dec 31, 2024, up from $81.3M.
- Net loss for Q4 2024 was $58.7M vs. $26.9M in Q4 2023; R&D spend rose to $56.3M from $18.4M.
- UCB exercised option to in-license KCNT1 candidate; Praxis eligible for up to ~$100M in milestones plus royalties.

## SEC filing metadata
- accession: 0001689548-25-000037
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/0001689548-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/prax-20250228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-25-000037
- JSON: https://secwatch.observer/filing/0001689548-25-000037.json
- Plain text: https://secwatch.observer/filing/0001689548-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.